Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01951950 · ClinicalTrials.gov registry record · Phase 1

Nicardipine vs Esmolol Craniotomy Emergence

A Phase 1 study of Brain Tumors, sponsored by Northwestern University.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT01951950: Completed Phase 1 study of Brain Tumors, sponsored by Northwestern University.

NCT01951950 is a Phase 1 study of Brain Tumors that has completed, run by Northwestern University. The registered enrollment target is 40 participants, below the 6,339-participant average among 10 other Brain Tumors trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01951950, a Phase 1 study of Brain Tumors, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Emergence hypertension is a common occurrence in patients emerging from general anesthesia. This elevation of arterial pressure is particularly concerning in patients undergoing craniotomy due to increased risk of morbidity and mortality in patients with altered intracranial elastance. Thus, identifying better methods to attenuate the hemodynamic changes associated with emergence from anesthesia can improve patient safety, especially in the neurosurgical patient. Study Hypothesis: Nicardipine is more effective than esmolol as a sole agent in maintaining blood pressure within goal range in the setting of emergence hypertension after craniotomy.

Conditions Studied

Interventions

  • DRUG Nicardipine
  • DRUG Esmolol

Study Locations (1)

Illinois

  • Northwestern Memorial Hospital - Chicago

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2013-09
Est. Completion 2014-05
Phase Phase 1
Northwestern University

1,209 total trials

What the finished NCT01951950 record still lists

NCT01951950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 6,339-participant average among 10 other Brain Tumors trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Brain Tumors appearing as the primary indexed condition, and to 2 interventions - of which Nicardipine is the first listed.

NCT01951950 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT01951950 about?

NCT01951950 is a clinical study titled "Nicardipine vs Esmolol Craniotomy Emergence". Emergence hypertension is a common occurrence in patients emerging from general anesthesia. This elevation of arterial pressure is particularly concerning in patients undergoing craniotomy due to increased risk of morbidity and mortality in patients with altered intracranial elastance. Thus, identif...

What is the current status of trial NCT01951950?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-09. Estimated completion is 2014-05.

What conditions does trial NCT01951950 study?

This clinical trial studies the following conditions: Brain Tumors.

What interventions are being tested in trial NCT01951950?

The interventions under investigation include: Nicardipine (DRUG), Esmolol (DRUG).

Who is sponsoring clinical trial NCT01951950?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01951950 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01951950's enrollment target sits among peer trials

40 9th of 10 higher than 2 of 10 other Brain Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Brain Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01951950, the US trial registry maintained by the National Library of Medicine. NCT01951950 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.